The characterization of exosomes from biological fluids of patients with different types of cancer

Yunusova, N. V.; Тамкович, С. Н.; Стахеева, М. Н.; Grigor’eva, Alina; Somov, A. K.; Tugutova, E. A.; Коломиец, Л. А.; Molchanov, Sergey V.; Афанасьев, С. Г.; Какурина, Г. В.; Choinzonov, E. L.; Кондакова, И. В.

doi:10.1063/1.5001659

Cited by 7 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[31] This approach has been reported multiple times: Yunusova reports the use of CD9, CD63, CD81, and CD24 specific antibodies in order to screen EVs from biological fluids of patients suffering from varied cancers, namely stage IIIB, C ovarian cancer, T2-4N0-2M0 colorectal cancer, and stage T2-4N0-2M0 squamous cell head and neck carcinoma, thus, studying the different proteins on their surfaces by flow cytometer when the EVs were adsorbed onto latex beads. [52] Theodoraki has also used this method by immobilizing the EVs on streptavidin-labeled beads, along with a secondary detection antibodies with a fluorescent label to analyze both the proteins presented on the surface of the EV and its content (after lysis), with a LOD in the femtomolar range (Figure 2F). [31] Sharma et al have used flow cytometry to capture and characterize melanoma-derived CSPG4 + EVs present in serum samples which were subsequently used to differenti-ate between patients with early-stage cancer and patients with an advanced-stage cancer.…”

Section: Fluorescent Flow Cytometrymentioning

confidence: 99%

Nanostructured‐Based Optical Readouts Interfaced with Machine Learning for Identification of Extracellular Vesicles

Mata

Jeanne

Jalali

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are shed from cancer cells into body fluids, enclosing molecular information about the underlying disease with the potential for being the target cancer biomarker in emerging diagnosis approaches such as liquid biopsy. Still, the study of EVs presents major challenges due to their heterogeneity, complexity, and scarcity. Recently, liquid biopsy platforms have allowed the study of tumor‐derived materials, holding great promise for early‐stage diagnosis and monitoring of cancer when interfaced with novel adaptations of optical readouts and advanced machine learning analysis. Here, recent advances in labeled and label‐free optical techniques such as fluorescence, plasmonic, and chromogenic‐based systems interfaced with nanostructured sensors like nanoparticles, nanoholes, and nanowires, and diverse machine learning analyses are reviewed. The adaptability of the different optical methods discussed is compared and insights are provided into prospective avenues for the translation of the technological approaches for cancer diagnosis. It is discussed that the inherent augmented properties of nanostructures enhance the sensitivity of the detection of EVs. It is concluded by reviewing recent integrations of nanostructured‐based optical readouts with diverse machine learning models as novel analysis ventures that can potentially increase the capability of the methods to the point of translation into diagnostic applications.

show abstract

Section: Fluorescent Flow Cytometrymentioning

confidence: 99%

Nanostructured‐Based Optical Readouts Interfaced with Machine Learning for Identification of Extracellular Vesicles

Mata

Jeanne

Jalali

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…В настоящее время среди растворимых высокои низкомолекулярных компонентов асцита ведется активный поиск дополнительных прогностических и предикторных факторов, позволяющих уточнить молекулярный фенотип и персонифицировать лечение больных РЯ [22,29,40]. Асцитические экзосомы и микровезикулы вследствие их высокой биологической активности также вовлечены в канцерогенез [41][42][43].…”

Section: компоненты асцитической жидкости при раке яичниковunclassified

Ascites as a subject of studies in ovarian cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is a highly heterogeneous disease characterized by multiple histological subtypes. High- grade serous ovarian carcinoma is the most common histological subtype of ovarian cancer. The majority of ovarian cancer patients present with malignant ascites at diagnosis. Peritoneal dissemination is one of the most unfavorable factors for tumor progression and recurrence. A more precise visualization of peritoneal carcinomatosis can be achieved by transabdominal ultrasound. However, the prognostic factors associated with malignant ascites in ovarian cancer are currently not well understood. Among the clinical parameters, the volume of ascites has the greatest information in terms of prognosis of disseminated ovarian cancer. Ovarian cancer with small-volume ascites has a more favorable therapeutic prognosis. Ascites is an easily accessible and valuable source of cellular and extracellular components contained in it that are involved in ovarian carcinogenesis. Ascites represents an accessible and valuable source of material to identify signals that influence tumor growth. At present, among the soluble high- and low molecular components of ascites, an active search for additional prognostic and predictor factors is being conducted, providing insights into the molecular mechanisms for clinical phenotypes of ovarian cancer.

show abstract

“…Источником экзосом могут быть опухолевые клетки и клетки микроокружения. Используя современные методы молекулярно-генетического анализа, возможно секвенирование всей экзосомальной ДНК, РНК, получение комплексной информации об опухоли для индивидуализации лечения и оценки риска прогрессирования [62].…”

Section: экзосомы и рак шейки маткиunclassified

Role of liquid biopsy in the detection and monitoring of cervical cancer

Каюкова

2019

Sib. onkol. ž.

View full text Add to dashboard Cite

Cervical cancer is one of the most common cancers among women of reproductive age. The cytological screening is not always effective and appropriate, therefore the search for new predictive markers of the cervical cancer are of great importance. there are no biomarkers for monitoring patients previously treated for cervical cancer. liquid biopsy is a new option of personalized approach to the detection and monitoring of cervical cancer. it is a set of methods for determining the derivatives of a tumor in biological media, most often in the blood: circulating tumor cells, circulating dNa, RNa, exosomes, etc.The purpose of the studywas to analyze data on the role of liquid biopsy in the diagnosis and monitoring of cervical cancer.Material and methods. We analyzed publications available from pubmed, Elibrary over the past 10 years.Results. Circulating tumor cells, circulating tumor dNa and exosomes are the most studied cancer non-invasive biomarkers. these circulating biomarkers play a key role in the understanding of cervical carcenogenesis, chemo-and radioresistance. currently, liquid biopsy is considered as a promising modern method for the detection and monitoring of cervical cancer. the diagnostic efficiency of this method is good, so it can be used for cervcal cancer screening. However, such statements require further research in this direction. in addition, given the emerging information on the molecular carcinogenesis of cervical cancer, liquid biopsy can also be used as a basis for the development of targeted therapy for locally advanced and generalized cervical cancer.Conclusion. Liquid biopsy is the non-invasive method of cervical cancer monitoring.

show abstract

The characterization of exosomes from biological fluids of patients with different types of cancer

Cited by 7 publications

References 15 publications

Nanostructured‐Based Optical Readouts Interfaced with Machine Learning for Identification of Extracellular Vesicles

Nanostructured‐Based Optical Readouts Interfaced with Machine Learning for Identification of Extracellular Vesicles

Ascites as a subject of studies in ovarian cancer

Role of liquid biopsy in the detection and monitoring of cervical cancer

Contact Info

Product

Resources

About